Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusions:~* Patients with mild-to-moderate asthma for at least 6 months prior to Visit 1 (as defined in the GINA Guidelines) which is unlikely to exacerbate during the study (e.g., due to seasonal allergen exposure).~* Patients must be on a stable dose of Inhaled Corticosteroids (ICS) for at least 30 days prior to Visit 1. Patients on a combination of ICS/LABA must discontinue the use of LABA and must be on a stable dose of ICS for 30 days prior to Visit 1.~* Qualifying spirometry at Visit 1 demonstrates highest FEV1 is ≤ 85% and ≥ 60% of predicted for age, height, and gender using NHANES III (NHANES 2010) when bronchodilator medications have been withheld the appropriate length of time per the List of Concomitant Medications (Appendix III)~* Patient demonstrates reversibility with an increase in FEV1 of 12% and 200 mL after the administration of 360 µg of albuterol.~* Highest pre-dose FEV1 at Visits 2, 4, 6, 8, and 10 must be within 25% of the qualifying FEV1 at Visit 1~Exclusions:~* Patients with any clinically significant respiratory conditions other than mild to moderate asthma, such as COPD, active tuberculosis, or history of interstitial lung disease~* Patients with a severe asthma exacerbation requiring hospitalization in the previous 12 months~* Patient is not able to withhold use of inhaled short-acting beta-agonist (SABA) for at least 6 hours prior to visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental 1 (Type: EXPERIMENTAL): Formoterol Fumarate in the Pressair Pressair Dry Powder Inhaler (DPI), Low Dose
- Experimental 2 (Type: EXPERIMENTAL): Formoterol fumarate in the Pressair Dry Powder Inhaler (DPI), High Dose
- Active Comparator 1 (Type: ACTIVE_COMPARATOR): Foradil Aerolizer, Low Dose
- Active Comparator 2 (Type: ACTIVE_COMPARATOR): Foradil Aerolizer, High Dose
- Placebo (Type: PLACEBO_COMPARATOR): Dose matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).